Search Results
Predictors and outcomes of extramedullary disease in multiple myeloma
Predicting outcomes in patients with R/R MM undergoing CAR T-cell therapy: the MyCARe model
Predicting Overall Survival For Solitary Bone Plasmacytoma
Dr. Munshi on diagnosis and risk assessment in multiple myeloma | Dana-Farber Cancer Institute
The immune microenvironment predicts sustained MRD-negativity after D-KRd treatment for myeloma
How Personalized Is Myeloma Treatment and How Is Changing? Introducing the Individual Risk Model
Plasma Cell Leukemia in the Era of Novel Agent Therapy
Multimodal prediction of survival in myeloma: combining MRD testing with MALDI-TOF MS & imaging
“TGF-β: An Emerging Therapeutic Target in Multiple Myeloma” by Ehsan Malek, MD
New MRD monitoring techniques could be most accurate predictor of relapse in MM patients
Dr Elisabet Manasanch Highlights MRD Assessment Accuracy in Predicting Treatment Progression
High Risk Myeloma: How and should it be treated differently?
